Zepbound Pregnancy & Lactation Safety: What the Evidence Actually Shows

What Is Zepbound and How Does It Work?

Zepbound is a once-weekly subcutaneous injection of tirzepatide approved by the FDA in November 2023 for chronic weight management in adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity. Understanding its mechanism matters when assessing fetal risk, because both receptors it targets are expressed in developing embryonic tissue.

Dual GIP and GLP-1 Receptor Agonism

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 39-amino-acid synthetic peptide that binds and activates both receptors with comparable potency. GLP-1 receptors slow gastric emptying, reduce appetite signaling in the hypothalamus, and stimulate glucose-dependent insulin secretion. GIP receptors amplify insulin release and appear to modulate adipose tissue metabolism and central satiety circuits through pathways distinct from GLP-1 [1].

The additive effect of hitting both targets produced the weight loss numbers that set tirzepatide apart. In SURMOUNT-1 (N=2,539, NEJM 2022), participants receiving 15 mg tirzepatide lost a mean of 20.9% of body weight at 72 weeks, compared with 3.1% in the placebo arm (P<0.001) [2].

Why Receptor Distribution Matters for Pregnancy

GLP-1 receptors are expressed in the pancreas, brain, heart, and lungs of developing rodent embryos as early as gestational day 10 [3]. GIP receptors appear in rodent placental tissue. Neither receptor has been thoroughly mapped in first-trimester human embryos, meaning the full scope of potential developmental disruption remains unknown. That receptor-distribution gap underpins why regulatory agencies treat all GLP-1-class and dual-agonist drugs as contraindicated during organogenesis.

What Animal Reproductive Toxicology Shows

Animal data are the primary evidence base for assessing teratogenic risk with tirzepatide, because no adequate human pregnancy data exist.

Rat and Rabbit Embryo-Fetal Development Studies

In rat embryo-fetal development studies conducted by Eli Lilly, tirzepatide caused dose-dependent fetal skeletal malformations and reduced fetal weight at 0.9 times the human exposure at the 5 mg dose (based on plasma AUC). Visceral malformations and increases in early embryonic deaths occurred at higher exposures [4]. These effects emerged at doses below the lowest approved human therapeutic dose, which is a meaningful signal.

Rabbit studies showed similar findings: reduced fetal weight and increased post-implantation loss at exposures approximately equal to the human 5 mg dose AUC. In pre- and postnatal development studies in rats, tirzepatide reduced pup body weight and delayed developmental landmarks through the end of the lactation period [4].

Limits of Animal-to-Human Extrapolation

Rats and rabbits are not humans. Rodent placental anatomy, gestational length, and drug-transfer kinetics differ substantially from human pregnancy. Animal reproductive toxicology reliably identifies hazards but cannot precisely predict the magnitude of human fetal risk. The absence of human data does not mean the drug is safe. It means the risk remains uncharacterized, which is a different and in some ways more difficult clinical problem.

Human Pregnancy Data: What We Know and Do Not Know

No Controlled Human Trials

No prospective randomized trial has studied tirzepatide in pregnant women. Participants in SURMOUNT-1 and SURMOUNT-2 were required to use effective contraception, and any participant who became pregnant was withdrawn from the study. Pregnancy outcomes in those withdrawn participants were not systematically reported in the primary publications [2].

The Pregnancy Exposure Registry

Eli Lilly maintains a pregnancy exposure registry for Zepbound. Patients or their clinicians can enroll by calling 1-800-545-6962. As of the most recent Zepbound prescribing information update (March 2024), the registry has not accumulated sufficient cases to allow any quantitative risk estimate [4]. This is not unusual for a drug approved in late 2023, but it means clinicians have no registry-derived safety signal to cite in either direction.

Inadvertent Exposures

Case reports of inadvertent first-trimester tirzepatide exposure will accumulate as the drug's prescription volume grows. Semaglutide, a GLP-1 agonist with a longer market history, has similarly sparse formal pregnancy safety data despite millions of prescriptions. A 2023 Danish cohort published in NEJM Evidence (N=432 exposed pregnancies) found a 4.6% major congenital anomaly rate in GLP-1 receptor agonist-exposed pregnancies vs. 4.0% in matched controls, a difference that did not reach statistical significance but was based on a heterogeneous drug class and short follow-up [5]. That study cannot be directly applied to tirzepatide's GIP-GLP dual mechanism.

Clinical Decision Framework: Managing the Reproductive-Age Patient on Zepbound

The following stepwise approach reflects current FDA labeling, Endocrine Society guidance, and available pharmacokinetic data. It is intended as a practical workflow for prescribers, not a substitute for individualized clinical judgment.

1. Before prescribing: Confirm pregnancy status. Discuss contraception. Document a shared-decision conversation about the 2-month washout requirement.
2. During treatment: Confirm ongoing contraception at each visit. Screen for pregnancy symptoms if a patient reports any missed or unusual cycle.
3. If planning pregnancy: Stop tirzepatide at least 2 months before attempting conception. Tirzepatide's mean elimination half-life is approximately 5 days; 5 half-lives equals 25 days for pharmacokinetic clearance, but the 2-month window provides an added safety margin to account for variability and ensures the drug is absent during early organogenesis (days 17 to 56 post-fertilization).
4. If inadvertent pregnancy occurs: Discontinue immediately. Refer to maternal-fetal medicine. Enroll in the Lilly pregnancy registry.
5. Postpartum weight management: If the patient is not breastfeeding and wishes to restart, the decision should weigh the metabolic burden of postpartum weight retention against absence of infant exposure risk.

FDA Labeling and Regulatory Classification

The Zepbound prescribing information states: "Based on findings in animal reproduction studies, Zepbound may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with Zepbound and for 2 months after the last dose" [4]. The labeling does not use a legacy A/B/C/D/X category (the FDA retired that system in 2015), but the risk summary language is unambiguous about contraindication in pregnancy.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states that GLP-1 receptor agonists "should be discontinued at least 2 months before planned conception" [6]. Tirzepatide falls within the scope of that recommendation by drug class, even though the guideline was finalized shortly before tirzepatide's obesity indication approval.

Lactation Safety: What Is Known

No Human Milk Transfer Data

The Zepbound prescribing information states that no data exist on the presence of tirzepatide in human milk, its effects on the breastfed infant, or its effects on milk production [4]. Given this complete absence of data, the FDA label recommends against breastfeeding during treatment and for 1 month after the last dose, a window derived from pharmacokinetic clearance estimates rather than actual lactation studies.

Pharmacokinetic Considerations

Tirzepatide is a large peptide (molecular weight approximately 4,813 Da). Large peptides generally transfer poorly across mammary epithelium into breast milk, and even if present in milk, they are likely to be degraded in the infant's gastrointestinal tract before systemic absorption. This reasoning has led some clinicians to consider GLP-1 agents lower risk in lactation than in pregnancy.

That reasoning is pharmacologically plausible but clinically unproven for tirzepatide. GIP and GLP-1 receptors are expressed in neonatal intestinal tissue, and the neonatal GI tract is substantially more permeable than the adult gut. A drug degraded in an adult's stomach might exert local intestinal effects or even partial systemic absorption in a newborn. Until human lactation data exist, the pharmacokinetic argument for safety is speculative.

Comparison With Semaglutide Lactation Data

Semaglutide (Ozempic, Wegovy), the closest comparator by drug class, has similarly absent human lactation data. No peer-reviewed study has measured semaglutide concentrations in human breast milk. The National Institutes of Health LactMed database lists tirzepatide as "no data available" as of its most recent update [7]. Clinicians should not extrapolate a safety assumption from semaglutide to tirzepatide, because tirzepatide's GIP receptor activity adds a pharmacodynamic dimension that semaglutide does not share.

Obesity in Pregnancy: The Competing Clinical Risk

Why the Contraindication Creates a Dilemma

Obesity in pregnancy carries serious, well-documented risks. A 2020 meta-analysis published in PLOS Medicine (72 studies, N=1.2 million pregnancies) found that obesity was associated with a 2.5-fold increased risk of gestational diabetes, a 1.6-fold increased risk of preeclampsia, and a 34% higher rate of cesarean delivery compared with normal-weight pregnancies [8]. For patients who lost 15 to 20% of body weight on Zepbound and then stopped for conception, weight regain before and during pregnancy is a real concern.

What Happens to Weight After Stopping

SURMOUNT-4 (N=670) examined weight regain after tirzepatide withdrawal. Participants who stopped tirzepatide after 36 weeks of treatment and switched to placebo regained, on average, 14% of their original body weight over the subsequent 52 weeks, recovering roughly two-thirds of the weight they had lost [9]. This pharmacological dependency has direct implications for preconception counseling: patients and clinicians need to plan weight-maintenance strategies that do not involve tirzepatide during the pre-conception and gestational period.

Behavioral interventions, dietary modification, and continued physical activity can blunt post-discontinuation weight regain, though they rarely replicate the magnitude of pharmacologically assisted loss. Metformin is sometimes considered in the setting of polycystic ovary syndrome (PCOS) or insulin resistance; it has a substantially longer safety record in pregnancy and is not contraindicated [10].

PCOS, Fertility, and Zepbound

Weight loss of 10 to 15% can restore ovulation in anovulatory women with PCOS. Tirzepatide's substantial weight loss effect may improve spontaneous fertility in this population, creating a scenario in which a patient conceives while still on the drug or before completing the 2-month washout. Clinicians prescribing Zepbound to women with PCOS-associated infertility should discuss this explicitly and ensure contraception is in place until the patient has deliberately completed a washout prior to conception attempts.

Contraception Guidance During Zepbound Treatment

Which Contraceptive Methods Are Compatible

All contraceptive methods are pharmacologically compatible with tirzepatide, with one practical consideration: tirzepatide slows gastric emptying, which may reduce the absorption of orally administered drugs during the first few hours after a dose. Oral contraceptive pills taken on the same day as a tirzepatide injection may have modestly reduced peak plasma concentrations [4].

The FDA label advises that patients using oral hormonal contraceptives switch to a non-oral method (implant, intrauterine device, injectable depot progestin) or add a barrier method for 4 weeks after tirzepatide initiation and for 4 weeks after each dose escalation. This is a precautionary recommendation, not evidence of contraceptive failure in a clinical trial.

Practical Counseling Point

An IUD or subdermal implant avoids any interaction concern entirely. For patients who prefer oral contraception, taking the pill at least 1 hour before or several hours after the weekly tirzepatide injection minimizes any gastric-emptying overlap, though even this timing has not been studied in a dedicated pharmacokinetic trial.

Summary of Clinical Recommendations

Clinicians prescribing Zepbound to women of reproductive age should cover the following at each relevant visit:

• Confirm the patient is not pregnant before initiating and at intervals during treatment.
• Require effective non-oral contraception, or oral contraception plus a barrier method during dose escalation.
• Discuss the 2-month pre-conception washout requirement. Document this discussion.
• Plan an alternative weight-maintenance strategy before conception is attempted.
• If inadvertent pregnancy occurs, stop the drug immediately and enroll in the Lilly pregnancy registry (1-800-545-6962).
• Do not recommend breastfeeding during treatment or within 1 month of the last dose.
• Inform patients that weight regain after discontinuation averages roughly 14% of original body weight at 1 year (SURMOUNT-4), and set realistic expectations before stopping.

The FDA-approved tirzepatide prescribing information remains the authoritative document for contraindication language. As registry data accumulate and case series emerge, the evidence base will evolve. Patients and providers should check the Lilly registry outcomes and the FDA drug safety database for updates before each clinical encounter involving reproductive planning.